OIS@AAO
Nancy Lurker, president and CEO, reports data from two Phase III trials for Durasert’s use in treating uveitis. The company plans to file an NDA…
Read MoreOIS Co-chair and Clarus Funds Managing Director Emmett T. Cunningham Jr., MD, PhD, MPH, delivered a complete overview of the new ophthalmology treatments. In this…
Read MoreVicken Karageozian, MD, president and chief medical officer, Allegro Ophthalmics, shares how Allegro has “taken a lot of risk out of the equation” after reporting…
Read MoreKevin Waltz, MD, partner, Eye Surgeons of Indiana, Mynosys, explains how the company’s Zepto device helps create the “round, consistent” anterior lens capsulotomy in nearly…
Read MoreBill Burns, president and CEO, Encore Vision, introduces OIS to Encore Vision, which has the “sole purpose” of developing a treatment for presbyopia. Burns says…
Read MoreJoseph Boorady, president and CEO, TearScience, shares details on recent studies that demonstrated LipiFlow’s ability to deliver long-term relief for dry eye sufferers. He also…
Read MoreBernhard Günther, managing director and co-founder, Novaliq GmbH, tells OIS-TV about Novaliq’s new CEO, Christian Roesky, PhD. Günther will assume the role of chief innovation…
Read MoreMegan Baldwin, PhD, CEO and managing director, Opthea Ltd., introduces OPT-302, a new vehicle for targeting the VEGF pathway and wet age-related macular degeneration (AMD).…
Read MoreJim Mazzo, global president of ophthalmic devices, Carl Zeiss Meditec, explains why ophthalmology continues to draw interest from new players. He also reveals how he’s…
Read MoreJohn Kilcoyne, president and CEO, ReVision Optics, shares the company’s plans for a commercial rollout of Raindrop, the firm’s promising corneal inlay. Participant: John Kilcoyne…
Read MoreAmar Sawhney, president, CEO, and chairman of Ocular Therapeutix, gives details on his company’s new collaboration with Regeneron to develop a sustained-release formulation of the…
Read MoreVince Anido, PhD, CEO and chairman, Aerie Pharmaceuticals, sees hopeful signs in the FDA’s process to review combination therapies. This positioning could benefit Aerie in…
Read MoreSUBSCRIBE TO OIS NEWS
Get Our Weekly Newsletter About The Latest In Ophthalmic Innovation.
We respect your privacy and promise to never send you spam.